
GSK’s Nucala data insufficient for US COPD approval
pharmafile | September 10, 2018 | News story | Sales and Marketing | COPD, FDA, GSK, Nucala, US, pharma
GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA rejecting the application for the drug’s use in the maintenance treatment for the reduction of exacerbations in coronary pulmonary obstructive disorder (COPD).
GSK confirmed that its inhaled corticosteroid-based maintenance treatment was knocked back due to requests submitted in a clinical response letter for more clinical data to support an approval, a request which the company has confirmed it is working closely with the US regulator to achieve.
The company’s submission included data from two trials, one of which demonstrated that Nucala showed a “statistically significant reduction in the frequency of moderate and severe exacerbations” compared to placebo in patients with a broad range of blood eosinophil counts. However, in the second trial the drug failed to reduce the frequency of such exacerbations to a statistically significant degree.
Nucala became the first IL-5 inhibitor to secure approval form the FDA, for severe asthma associated with elevated eosinophil levels in 2015.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …





